
Vandetanib is a targeted drug for the treatment of medullary thyroid lesions (MTC), especially in patients with unresectable locally advanced or metastatic medullary thyroid lesions. It has become an important drug in the treatment of medullary thyroid lesions by inhibiting a variety of tyrosine kinases and blocking the growth and spread of diseased cells.
The place of Vandetanib in the treatment of lesions
Vandetanib plays an important role in the treatment of medullary thyroid lesions (MTC), especially for patients with unresectable locally advanced or metastatic medullary thyroid lesions. It significantly prolongs the progression-free survival of patients by inhibiting a variety of tyrosine kinases and blocking the growth and spread of diseased cells.
Mechanism of action of Vandetanib
Vandetanib blocks the growth and spread of diseased cells by inhibiting a variety of tyrosine kinases, including EGFR, VEGFR, and RET. This multi-target inhibition effect makes it effective in the treatment of medullary thyroid lesions, helping patients control disease progression.
Indications for Vandetanib
Vandetanib is indicated for patients with unresectable locally advanced or metastatic medullary thyroid lesions. It helps patients prolong progression-free survival and improve quality of life by inhibiting the growth and spread of diseased cells.
Vandetanib plays a significant role in the treatment of medullary thyroid lesions, and its therapeutic effect has been widely recognized. Next, we will detail the therapeutic effects of Vandetanib.
Therapeutic effects of Vandetanib
Vandetanib has shown significant therapeutic efficacy in the treatment of medullary thyroid lesions, particularly in patients with unresectable locally advanced or metastatic medullary thyroid lesions. It significantly prolongs progression-free survival by inhibiting multiple tyrosine kinases.
Prolongs progression-free survival
By inhibiting a variety of tyrosine kinases, Vandetanib blocks the growth and spread of diseased cells, significantly prolonging the progression-free survival of patients with medullary thyroid lesions. Clinical trial data showed that progression-free survival was significantly better in the Vandetanib treatment group than in the control group.
Improve quality of life
Vandetanib not only prolonged progression-free survival, but also significantly improved patients' quality of life. The patient's symptoms were effectively controlled during the medication, and the quality of life was significantly improved.
The therapeutic effect of Vandetanib is significant, but patients should be aware of its possible side effects and related management measures when using it. Next, we will introduce the post-use review program of Vandetanib.
Vandetanib post-use review items
The use of Vandetanib needs to be reviewed regularly, and patients should regularly monitor ECG, liver function, and blood levels during the drug period to prevent possible serious adverse reactions.
Monitor the ECG regularly
Vandetanib may cause QT interval prolongation, and patients should have their ECG monitored regularly during treatment. If the QT interval is prolonged, your doctor may adjust the dose or stop taking the medication until the ECG returns to normal.
Monitor liver function regularly
Vandetanib may cause hepatotoxicity, and patients should have regular monitoring of liver function during use. The doctor will adjust the dose of the drug or stop the drug according to the patient's liver function indicators.
Vandetanib is a prescription drug, and patients should strictly follow the doctor's instructions when using it and have regular re-examinations to prevent possible serious adverse reactions.